Back to Search
Start Over
A stable cell line inducibly expressing hERG1a/1b heteromeric channels
- Source :
- J Pharmacol Toxicol Methods
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Heterologously expressed hERG channels represent a mainstay of in vitro drug safety screens intended to mitigate risk of cardiac IKr block and sudden cardiac death. This is true even as more channel types are adopted as part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) intended to elevate specificity and thus enhance throughput of promising lead drugs. Until now, hERG1a homomeric channels have been used as a proxy for IKr despite a wealth of evidence showing that hERG1a/1b heteromers better represent native channels in terms of protein abundance and channel biophysical and pharmacological properties. Past efforts to create a stable hERG1a/1b cell line were met with unpredictable silencing of hERG1b expression despite stable integration of the gene into the HEK293 cell genome. Here we report a new cell line stably expressing hERG1a, with hERG1b reliably controlled by an inducible promoter sensitive to doxycycline. Co-immunoprecipitation, Western blot analysis and patch-clamp electrophysiology confirm the heteromeric composition of the expressed channels. Association with hERG1b was found to promote hERG1a protein levels and enhance membrane current levels. Optimal conditions for drug screening and experimental investigation were achieved at 24 h exposure to 100 ng/ml doxycycline. Differences in pharmacological sensitivity between homomeric and heteromeric channels were observed for dofetilide and ebastine, but not fluoxetine, as evaluated by their IC50 values. Using these values in the O'Hara-Rudy-CiPA in silico model revealed discrepancies in pro-arrhythmia risk, implying the hERG1a homomeric platform overestimates risk for these two drugs. Dofetilide block was use-dependent and faster for hERG1a/1b than hERG1a channels, whereas ebastine showed considerable block at rest and had a slower progression for hERG1a/1b channels. The hERG1a/1b cell line thus represents an advanced model for contemporary drug safety screening assays such as CiPA that employ IC50 values to estimate risk of proarrhythmia in computational models of ventricular cardiomyocytes. This novel technology fulfills an unmet need to enhance specificity and foster a safe yet expanded drug development pipeline.
- Subjects :
- ERG1 Potassium Channel
In silico
hERG
Dofetilide
030204 cardiovascular system & hematology
Biology
Toxicology
030226 pharmacology & pharmacy
Article
03 medical and health sciences
0302 clinical medicine
medicine
Humans
Homomeric
Repolarization
Myocytes, Cardiac
Pharmacology
Proarrhythmia
HEK 293 cells
Arrhythmias, Cardiac
medicine.disease
Ether-A-Go-Go Potassium Channels
Cell biology
HEK293 Cells
Drug development
biology.protein
medicine.drug
Subjects
Details
- ISSN :
- 10568719
- Volume :
- 110
- Database :
- OpenAIRE
- Journal :
- Journal of Pharmacological and Toxicological Methods
- Accession number :
- edsair.doi.dedup.....92911fe8bf3f5a8534896d15fe35a386